GlassScriptPhysician profile
Daniel K Short
NPI 1376547257
$327,720.51
in general payments reported to CMS, 2019-2025
19 companies · $23K in 2025
The $23K reported for 2025 was more than what 93% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $57K · 2020: $47K · 2021: $27K · 2022: $75K · 2023: $53K · 2024: $45K · 2025: $23K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $101K · Travel and Lodging: $7,837 · Consulting Fee: $6,088 · Food and Beverage: $4,099 · Honoraria: $2,040 · Education: $81.01.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $100,825.00 |
| Travel and Lodging | $7,836.92 |
| Consulting Fee | $6,088.00 |
| Food and Beverage | $4,099.20 |
| Honoraria | $2,040.00 |
| Education | $81.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $254,264.92 | 2019-2025 | Mounjaro |
| Novo Nordisk INC | $25,109.07 | 2019-2025 | Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23,803.45 | 2019-2023 | Jardiance |
| Sanofi-Aventis U.S. LLC | $7,742.60 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $5,397.01 | 2019 | |
| Horizon Therapeutics Plc | $5,255.55 | 2021-2023 | Tepezza |
| Merck Sharp & Dohme LLC | $4,043.52 | 2019 | |
| Dexcom, INC. | $923.44 | 2021-2025 | Dexcom G7 Gss (161), Dexcom G6 Transmitter, Dexcom Stelo Glucose Biosensor |
| Astrazeneca Pharmaceuticals LP | $240.61 | 2019 | |
| Abbott Laboratories | $144.34 | 2025 | Freestyle Libre 3 |
| Insulet Corporation | $125.00 | 2024 | Omnipod |
| Bayer Healthcare Pharmaceuticals INC. | $121.01 | 2023 | |
| Sequel Med Tech, LLC | $115.22 | 2025 | Twiist |
| Ascendis Pharma Endocrinology INC | $111.90 | 2025 | Yorvipath |
| Cequr Corporation | $96.11 | 2024 | Cequr Simplicity |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $78.27 | 2019 | |
| Amarin Pharma, INC. | $67.70 | 2022 | |
| Tandem Diabetes Care, INC. | $64.04 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Corcept Therapeutics | $16.75 | 2025 | Korlym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Short listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.